常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-3.91/-0.31
|
|
企业价值
188.40M
|
| 资产负债 |
|
每股账面净值
0.04
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
1.88M
|
|
每股收益
0.04
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/11/08 12:11 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. |

6.24 
